Incyte Corporation | |
---|---|
公司类型 | 上市公司 |
股票代号 | NASDAQ:INCY NASDAQ-100 Component S&P 500 Component |
成立 | 1991年 |
代表人物 | Hervé Hoppenot(总裁兼CEO) |
总部 | 美国特拉华州威尔明顿 |
产业 | 制药 |
营业额 | ▲ $US 15亿(2017) |
净利润 | ▲ $US $3亿(2017) |
总资产 | ▲ $US 15.04亿(2017) |
资产净值 | ▲ $US 16.32亿(2017) |
员工人数 | ~700[1] |
网站 | www.incyte.com |
备注 | [2] |
因赛特(Incyte, Corp),又译英赛德,是一家美国制药公司。
历史
该公司生产有治疗骨髓纤维化的Jakafi[3]。此外和还和礼来制药开发有治疗类风湿性关节炎的baricitinib[4][5],但此药物因安全性问题在2017年4月被FDA禁止销售[6][7]。
参考文献
- ↑ 1.0 1.1 Scott Goss. Incyte is Delaware Bio Company of the Year, again. delawareonline.com. 2 Mar 2015 [2 Mar 2015].
- ↑ Incyte Corporation, Form 10-K (SEC filing), Incyte Corporation, 20122012-02-22 [2012-05-06], Commission File Number: 0-27488
- ↑ Natoli, Cori Anne, Incyte looks to ride on drug's success, The News Journal, 2012-05-05 [2012-05-06]
- ↑ Lilly, Incyte Treatment Shows Positive Results. www.insideindianabusiness.com. 9 Dec 2014 [2 Mar 2015].
- ↑ Baricitinib (pdf). Statement on a nonproprietary name adopted by the USAN council. American Medical Association. [2019-01-11].
- ↑ Ramsey, L. The FDA shot down a new rheumatoid arthritis drug — and the companies that make the drug are tumbling. Business Insider. 2017-04-17 [2019-01-11].
- ↑ Grant, Ch. Surprise FDA Rejection Will Sting This Biotech. The Wall Street Journal. 2017-04-14 [2019-01-11].
外部链接
-
- Incyte的商业数据:
- SEC filings